title: Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes.
abstract: Stromal-derived factor-1 (SDF-1) is a critical chemokine for endothelial progenitor cell (EPC) recruitment to areas of ischemia, allowing these cells to participate in compensatory angiogenesis. The SDF-1 receptor, CXCR4, is expressed in developing blood vessels as well as on CD34+ EPCs. We describe that picomolar and nanomolar concentrations of SDF-1 differentially influence neovascularization, inducing CD34+ cell migration and EPC tube formation. CD34+ cells isolated from diabetic patients demonstrate a marked defect in migration to SDF-1. This defect is associated, in some but not all patients, with a cell surface activity of CD26/dipeptidyl peptidase IV, an enzyme that inactivates SDF-1. Diabetic CD34+ cells also do not migrate in response to vascular endothelial growth factor and are structurally rigid. However, incubating CD34+ cells with a nitric oxide (NO) donor corrects this migration defect and corrects the cell deformability. In addition, exogenous NO alters vasodilator-stimulated phosphoprotein and mammalian-enabled distribution in EPCs. These data support a common downstream cytoskeletal alteration in diabetic CD34+ cells that is independent of growth factor receptor activation and is correctable with exogenous NO. This inability of diabetic EPCs to respond to SDF-1 may contribute to aberrant tissue vascularization and endothelial repair in diabetic patients.
authors.affiliation: Division of Nephrology, Hypertension & Transplantation, University of Florida, P.O. Box 100224, Gainesville, FL 32610-0267, USA. segalms@medicine.ufl.edu
authors.forename: Mark S
authors.initials: MS
authors.lastname: Segal
authors.forename: Ronak
authors.initials: R
authors.lastname: Shah
authors.forename: Aqeela
authors.initials: A
authors.lastname: Afzal
authors.forename: Cecile M
authors.initials: CM
authors.lastname: Perrault
authors.forename: Kyunghee
authors.initials: K
authors.lastname: Chang
authors.forename: Anna
authors.initials: A
authors.lastname: Schuler
authors.forename: Elaine
authors.initials: E
authors.lastname: Beem
authors.forename: Lynn C
authors.initials: LC
authors.lastname: Shaw
authors.forename: Sergio
authors.initials: S
authors.lastname: Li Calzi
authors.forename: Jeffrey K
authors.initials: JK
authors.lastname: Harrison
authors.forename: Roger
authors.initials: R
authors.lastname: Tran-Son-Tay
authors.forename: Maria B
authors.initials: MB
authors.lastname: Grant
mesh_terms: D018952:Antigens, CD34 / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects; D002478:Cells, Cultured; D054377:Chemokine CXCL12; D019743:Chemokines, CXC / Q000378:metabolism; D003599:Cytoskeleton / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism* / Q000473:pathology*; D042783:Endothelial Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D019169:Jurkat Cells; D007674:Kidney Diseases; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism* / Q000494:pharmacology; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000473:pathology
chemical_list: D018952:Antigens, CD34; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D019743:Chemokines, CXC; D009569:Nitric Oxide